
By Sneha S K and Sriparna Roy
(Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no progress is made in the next four months.
In a second letter to Novavax's board in less than a month, shared exclusively with Reuters on Wednesday, Shah Capital said it has become "increasingly disenchanted" with the company's weak COVID-19 vaccine sales.
"If I don't see changes happening, and if the company doesn't follow through in the next four months, then I think that is definitely a potential for a proxy fight," hedge fund founder Himanshu Shah said in an interview.
The fund said it still believes in Novavax's science and has increased its stake to about 8.3%, up from 7.2% in October.
However, it said it remains "at a complete loss" over the disappointing sales of Novavax's protein-based COVID-19 vaccine and is frustrated by its negligible market share.
DISCONNECT BETWEEN POTENTIAL AND EXECUTION
This marks another push from the activist investor for change after it withdrew a campaign against three board directors last year, following Novavax's licensing deal with Sanofi.
"It is reasonable to question whether Novavax and its partner are exhibiting a profound lack of competence or intentionally underperforming," the letter said.
Novavax's vaccine sold about 120,000 doses as of October 31, during the 2025-26 season that started in August, versus 14.5 million doses sold in the same period by two competitors, leaving Novavax's market share at about 0.8%, the letter said.
"Despite strong underlying science and evident market need, the disconnect between potential and execution is striking," the hedge fund said in its letter.
Earlier this month, Novavax pushed back its profitability target by a year to 2028.
Novavax has a high cost base, needs to be operationally profitable next year and should run more comprehensive trials, Shah said.
Shah values the company at $5 billion to $10 billion. Novavax's market capitalization is about $1.21 billion, according to LSEG data.
The fund urged the board to immediately form a committee to evaluate a sale and hire a qualified investment bank.
Shah has previously named Sanofi, Merck, GSK and AstraZeneca as potential buyers, but said he has not contacted them.
(Reporting by Sneha S K and Sriparna Roy in Bengaluru; Editing by Tasim Zahid)
LATEST POSTS
- 1
Research institutions tout the value of scholarship that crosses disciplines – but academia pushes interdisciplinary researchers out - 2
Overhaul Your Rest: Tips for a Serene Evening - 3
Watch Blue Origin's huge New Glenn rocket ace its epic landing on a ship at sea (video) - 4
IDF bans Android phones for senior officers, iPhones now mandatory, Army Radio reports - 5
Germany to create restitution council to return colonia-era acquired cultural artefacts
Figure out How to Stay away from Normal Handshaking Missteps
Poll: By a 2-to-1 margin, Americans say Trump has done more to raise prices than lower them
It's been 20 years since MTV's golden couple split. These producers saw it all unravel.
Flourishing in a Remote Workplace: Individual Techniques
Computerized Domains d: A Survey of \Vivid Undertakings\ Computer generated Reality Game
Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial
Clones of Stumpy, Washington D.C.'s beloved cherry blossom tree, have flowered for the first time
Egypt seeks to calm tourist fears over fallout of Iran war
10 Famous Frozen yogurt Flavors All over The Planet













